Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4938 - Heparinase enables reliable quantification of circulating tumor DNA from heparin plasma samples by droplet digital PCR

Date

11 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Hepatobiliary Cancers

Presenters

David Sefrioui

Citation

Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363

Authors

D. Sefrioui1, L. Beaussire2, F. Clatot3, A. Perdrix4, P. Michel5, F. Di Fiore5, N. Sarafan-Vasseur2

Author affiliations

  • 1 Gastroenterology, CHU Hôpitaux de Rouen-Charles Nicolle, 76031 - Rouen/FR
  • 2 Institute For Biomedical Research And Innovation, Inserm U1079, University of Rouen, 76000 - rouen/FR
  • 3 Department Of Medical Oncology, Henri Becquerel Center, 76000 - Rouen/FR
  • 4 Department Of Biopathology, Henri Becquerel Center, 76000 - Rouen/FR
  • 5 Department Of Oncology, CHU Charles Nicolle, 76031 - Rouen/FR
More

Resources

Abstract 4938

Background

Circulating tumor DNA has been highlighted as a potential “liquid biopsy”, which can be used to identify prognostic and predictive alterations in oncology. Heparin is often used as plasma anticoagulant source for tumor marker analysis such as CA19.9 or CA15.3 but corresponds also to an inhibitory of PCR not enabling ctDNA detection. We aimed to evaluate the impact of heparinase addition on heparinized plasma samples to recovery the possibility of ctDNA analysis on samples initially dedicated for tumor markers analysis.

Methods

Plasma samples were collected in heparinized (n = 194) and EDTA (n = 8) tubes from hormone receptor-positive metastatic breast cancer (HR+MBC) patients resistant to aromatase inhibitor (AI) treatment (n = 144) and from newly diagnosed pancreatic adenocarcinoma (PA) patients (n = 50). ESR1 and KRAS mutations were used as targets for ctDNA detection in HR+MBC and PA patients, respectively. ctDNA was detected by droplet digital PCR after an amplification step either without or with heparinase (H- and H+ respectively). PCR efficiency and ctDNA detection rate were compared between H- and H+ subgroups as well as with EDTA subgroup.

Results

Heparinase addition improved significantly PCR efficiency for 91/144 HR+MBC and 26/50 PA patients enabling ctDNA detection in 22/91 (24%) and 13/26 (50%) of these patients. Moreover, heparinase condition did not quantitatively and qualitatively alter the ctDNA detection for patients without heparin inhibition of PCR and comparable results for ctDNA detection were obtained between H+ and EDTA subgroups.

Conclusions

Heparinase addition allows removing the heparin inhibition on cfDNA amplification and to detect and quantify accurately ctDNA levels by dPCR in the heparinized plasma samples.

Clinical trial identification

Legal entity responsible for the study

Rouen University Hospital

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.